Fosfomycin (tromethamine)

Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].

Product Specifications

CAS Number

[78964-85-9]

Product Name Alternative

MK-0955 (tromethamine)

UNSPSC

12352005

Hazard Statement

H315-H317-H319-H334

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/fosfomycin-tromethamine.html

Purity

99.69

Solubility

H2O : 250 mg/mL (ultrasonic)

Smiles

C[C@@H]1O[C@@H]1P(O)(O)=O.OCC(CO)(N)CO

Molecular Formula

C7H18NO7P

Molecular Weight

259.19

Precautions

P261-P264-P272-P280-P284-P302+P352-P304+P340-P305+P351+P338-P362+P364-P501

References & Citations

[1]Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel) . 2017 Oct 31;6 (4) . pii: E24.|[2]Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29 (2) :321-47.|[3]Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5 (9) :659-69.|[4]Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5 (12) :941-50.